🔴 Haemonetics is trading 5.4% down today after a cut to full-year margin expansion guidance

Haemonetics is trading 5.39% lower at $117.42 as lower full-year operating-margin expansion guidance is the clearest company-specific explanation for the decline, though reporting does not confirm it caused the live move.

• Nov. 5’s report paired a quarterly beat with a margin expansion forecast cut to 0–50 basis points from 50–100, citing investment and cost pressures.
• Organic revenue growth guidance rose to 6%–9% from 4%–7%; the report highlighted CSL’s planned rollout.
• Healthcare weakness may add pressure; major indexes were higher.